Spark Therapeutics, Inc focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec) for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy and viable retinal cells. The company's gene therapy product candidates comprise SPK-8011 and SPK-8016 for hemophilia; SPK-7001 for choroideremia; and SPK-9001 for hemophilia B.
Read More…
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone888-772-7560
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$64.72 million
Profitability
Miscellaneous
Employees368
Next Earnings Date8/27/2019 (Estimated)
OptionableOptionable
Spark Therapeutics (NASDAQ:ONCE) Frequently Asked Questions
What is Spark Therapeutics' stock symbol?
Spark Therapeutics trades on the NASDAQ under the ticker symbol "ONCE."
How were Spark Therapeutics' earnings last quarter?
Spark Therapeutics Inc (NASDAQ:ONCE) released its earnings results on Tuesday, August, 7th. The biotechnology company reported ($0.77) EPS for the quarter, missing the consensus estimate of ($0.43) by $0.34. The biotechnology company had revenue of $25.19 million for the quarter, compared to analyst estimates of $29.44 million. Spark Therapeutics had a negative net margin of 397.68% and a negative return on equity of 48.70%. View Spark Therapeutics' Earnings History.
When is Spark Therapeutics' next earnings date?
What price target have analysts set for ONCE?
15 Wall Street analysts have issued 1 year price targets for Spark Therapeutics' shares. Their predictions range from $40.00 to $115.00. On average, they expect Spark Therapeutics' stock price to reach $90.7483 in the next year. This suggests that the stock has a possible downside of 10.0%. View Analyst Price Targets for Spark Therapeutics.
What is the consensus analysts' recommendation for Spark Therapeutics?
15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Spark Therapeutics in the last year. There are currently 13 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Spark Therapeutics.
What are Wall Street analysts saying about Spark Therapeutics stock?
Here are some recent quotes from research analysts about Spark Therapeutics stock:
- 1. According to Zacks Investment Research, "Spark Therapeutics, Inc. offers gene therapy. The Company's product candidate consist of SPK-RPE65, SPK-CHM, SPK-FIX which are in different clinical phases, for the treatment of additional blinding conditions, hematologic disorders and neurodegenerative diseases. Spark Therapeutics, Inc. is based in Philadelphia, Pennsylvania. " (8/14/2019)
- 2. William Blair analysts commented, "We see a sound strategic fit with Roche given its recent investment in hemophilia with the launch of Hemlibra (SPK-8011 in hemophilia A, SPK-8016 in hemophilia A patients with inhibitors and royalties from the fidanacogene elaparvovec collaboration with Pfizer), ophthalmology (Luxturna in the United States and royalties from the Luxturna EU launch), and neuroscience (SPK-1001 for CLN2) franchises." (2/26/2019)
Has Spark Therapeutics been receiving favorable news coverage?
News headlines about ONCE stock have trended positive recently, according to InfoTrie Sentiment. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Spark Therapeutics earned a coverage optimism score of 2.5 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 6.0 out of 10, meaning that recent press coverage is somewhat likely to have an impact on the company's share price in the near term. View News Stories for Spark Therapeutics.
Who are some of Spark Therapeutics' key competitors?
Some companies that are related to Spark Therapeutics include Seattle Genetics (SGEN), NOVOZYMES A/S/S (NVZMY), Neurocrine Biosciences (NBIX), Qiagen (QGEN), BIO-TECHNE (TECH), bluebird bio (BLUE), Adaptive Biotechnologies (ADPT), Repligen (RGEN), Moderna (MRNA), argenx (ARGX), China Biologic Products (CBPO), Ablynx (ABLYF), Allogene Therapeutics (ALLO), Crispr Therapeutics (CRSP) and Acceleron Pharma (XLRN).
What other stocks do shareholders of Spark Therapeutics own?
Who are Spark Therapeutics' key executives?
Spark Therapeutics' management team includes the folowing people:
- Mr. Jeffrey D. Marrazzo, Co-Founder, CEO & Director (Age 40)
- Dr. Katherine A. High, Co-Founder, Pres, Head of R&D and Director (Age 67)
- Mr. Stephen W. Webster, Chief Financial Officer (Age 58)
- Mr. Joseph W. La Barge Esq., J.D., Chief Legal Officer & Sec. (Age 48)
- Mr. Daniel R. Faga, Chief Bus. Officer (Age 39)
When did Spark Therapeutics IPO?
(ONCE) raised $88 million in an initial public offering on Friday, January 30th 2015. The company issued 5,500,000 shares at $15.00-$17.00 per share. J.P. Morgan and Credit Suisse served as the underwriters for the IPO and Cowen and Company and Sanford C. Bernstein were co-managers.
Who are Spark Therapeutics' major shareholders?
Spark Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (8.26%), BlackRock Inc. (7.16%), BlackRock Inc. (7.16%), Magnetar Financial LLC (2.30%), Alpine Associates Management Inc. (2.02%) and Paulson & CO. Inc. (1.97%). Company insiders that own Spark Therapeutics stock include Barge Joseph La, Daniel Faga, Hospital Of Philade Children's, Jeffrey D Marrazzo, John Furey, Katherine A High and Stephen W Webster. View Institutional Ownership Trends for Spark Therapeutics.
Which major investors are selling Spark Therapeutics stock?
ONCE stock was sold by a variety of institutional investors in the last quarter, including Syquant Capital Sas, JPMorgan Chase & Co., SG Americas Securities LLC, BlackRock Inc., BlackRock Inc., FNY Investment Advisers LLC, Carlson Capital L P and Morgan Stanley. View Insider Buying and Selling for Spark Therapeutics.
Which major investors are buying Spark Therapeutics stock?
ONCE stock was bought by a variety of institutional investors in the last quarter, including Paulson & CO. Inc., Boxer Capital LLC, TIG Advisors LLC, Renaissance Technologies LLC, Perceptive Advisors LLC, D. E. Shaw & Co. Inc., Twin Securities Inc. and Orbimed Advisors LLC. View Insider Buying and Selling for Spark Therapeutics.
How do I buy shares of Spark Therapeutics?
Shares of ONCE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Spark Therapeutics' stock price today?
One share of ONCE stock can currently be purchased for approximately $100.78.
How big of a company is Spark Therapeutics?
Spark Therapeutics has a market capitalization of $3.88 billion and generates $64.72 million in revenue each year. The biotechnology company earns $-78,820,000.00 in net income (profit) each year or ($2.11) on an earnings per share basis. Spark Therapeutics employs 368 workers across the globe.View Additional Information About Spark Therapeutics.
What is Spark Therapeutics' official website?
How can I contact Spark Therapeutics?
Spark Therapeutics' mailing address is 3737 MARKET STREET SUITE 1300, PHILADELPHIA PA, 19104. The biotechnology company can be reached via phone at 888-772-7560 or via email at [email protected]
MarketBeat Community Rating for Spark Therapeutics (NASDAQ ONCE)
MarketBeat's community ratings are surveys of what our community members think about Spark Therapeutics and other stocks. Vote "Outperform" if you believe ONCE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ONCE will underperform the S&P 500 over the long term. You may vote once every thirty days.
